Drugs / BHT-3009
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00103974 | Jul 2004 → Mar 2007 | multiple sclerosis | Bayhill Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00382629 | Feb 2006 → Jun 2007 | relapsing-remitting multiple sclerosis | Bayhill Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHT-3009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00382629 ↗ |
| Modality | Vaccine | “a tolerizing DNA vaccine encoding full-length human myelin basic protein” PMID 17698695 ↗ Aug 2007 |
| Route | Intramuscular | “BHT-3009 was administered as intramuscular injections” PMID 17698695 ↗ Aug 2007 |